The Serum Institute of India (SII) has developed India’s first indigenous vaccine against pneumonia. It is likely to be launched next week by Union Health Minister Harsh Vardhan, official sources said.
The vaccine which got market approval by Drug Regulator in July is touted to be much more affordable in comparison to existing ones manufactured by foreign companies.
The drug regulator gave nod to Pneumococcal Polysaccharide Conjugate vaccine, after reviewing the phase 1, 2 and 3 clinical trial data submitted by the Pune-based firm.
This vaccine is used for active immunisation against invasive disease and pneumonia caused by “Streptococcus pneumonia” in infants, the health ministry had said earlier,as per a PTI report. Serum Institute has conducted the phase 1, 2 and 3 clinical trials of the vaccine in India and African nation Gambia.
The vaccine will be much more affordable than the existing ones produced by Pfizer and GlaxoSmithKline, the sources said. “It has always been our endeavour to fulfil our prime minister’s dream for ‘vocal for local’ and ‘Making in India’ for the world.
“Moving towards prime minister’s clarion call of Atmanirbhar Bharat, we have achieved one more historical milestone during the lockdown period of COVID-19 pandemic by developing India’s first world-class indigenous pneumococcal conjugate vaccine (PCV) and obtained Indian licensure,” stated a letter written by Prakash Kumar Singh, Additional Director, Government and Regulatory Affairs at the Serum Institute of India (SII) addressed to Vardhan.